This retrospective analysis looked at 341 patients with HR-positive, HER2-negative metastatic breast cancer treated at Tianjin Medical University Cancer Institute and Hospital in China. The researchers compared three different CDK4/6 inhibitors—palbociclib, abemaciclib, and dalpiciclib—when combined with either an aromatase inhibitor or fulvestrant. The goal was to see if the specific drug choice affected how long patients stayed free from disease progression.
The study found that patients taking abemaciclib or dalpiciclib experienced longer progression-free survival compared to those taking palbociclib. Median follow-up times varied by drug group, with palbociclib at 15.6 months, abemaciclib at 10.9 months, and dalpiciclib at 18.2 months. Despite the shorter median follow-up for the abemaciclib group, the data suggested a benefit over palbociclib. The study also found that the choice of endocrine therapy did not significantly change survival outcomes.
Safety concerns were consistent with what is already known about these drugs, and no new safety signals were identified. However, because this was an observational study, it shows associations rather than proving that one drug caused the better survival times. The shorter follow-up for some groups also means the full picture of long-term outcomes is not yet clear. Readers should view these findings as supportive evidence for tailoring drug selection to patient needs, rather than definitive proof of superiority.
